A tumor of pure lepidic component is now considered adenocarcinoma-in-situ [3], so the fact that KRAS mutations were identified only in the minority invasive acinar component and not in the lepidic component suggests an evolutionary event in this patient. This evidence concerns the gene KRAS and adenocarcinoma.